-
Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary InterventionD Sibbing, D Aradi, D Alexopoulos et al. -
Genotyping to Guide Clopidogrel Treatment: An In-Depth Analysis of the TAILOR-PCI TrialNaveen L. Pereira, MBBS, FACC
-
Prasugrel versus clopidogrel in patients with acute coronary syndromesWiviott SD, Braunwald E, TRITON-TIMI 38 Investigators.
-
Osteoarthritis risk is reduced after treatment with ticagrelor compared to clopidogrel: a propensity score matching analysisMC Baker, YJ Weng, RH William et al.
-
Dual Antiplatelet Therapy Duration in Medically Managed Acute Coronary Syndrome Patients: Sub-Analysis of the OPT-CAD StudySicong Ma, Zaixin Jiang, YL Han et al.
-
Individualized antiplatelet therapy after drug-eluting stent deployment: Implication of clinical trials of different durations of dual antiplatelet therapyNakamura M, Kougame N, Iijima R et al.
-
Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trialYi Li, QM Jing, YL Han et al.
-
A Prospective, Multicenter, Randomized, Open-label Trial to Compare Efficacy and Safety of Clopidogrel vs. Ticagrelor in Stabilized Patients with Acute Myocardial Infarction after Percutan eous Coronary Intervention: rationale and design of the TALOS-AMI trialM-W Park, CJ Kim, K Chang et al.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
